Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
This clinical trial is testing a targeted medication called DFMO as a maintenance therapy for young patients with a specific, high-risk type of brain tumor called medulloblastoma. The goal is to see if this medicine can help prevent the cancer from coming back after standard treatments.
Children and young adults up to age 21 who have been diagnosed with certain high-risk or returned forms of medulloblastoma may be eligible to join. There are specific rules about your exact cancer type, past treatments, and overall health that the study team will review with you.
Participants will take the study medication, DFMO, to help keep the cancer under control. You will also have regular check-ups and medical tests so the doctors can monitor your health and see how well the treatment is working.
This study is currently recruiting participants at multiple medical centers, including locations in Arkansas and California. The study team can provide exact details on participating locations near you.
- 1Testing a targeted medication called DFMO to prevent brain tumor growth
- 2Open to patients aged 0 to 21 with specific high-risk medulloblastoma
- 3Currently recruiting participants at select medical centers
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.